Regular Aspirin Use May Lower Breast Cancer Risk

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 12
Volume 4
Issue 12

COLUMBUS, Ohio--Women who said they used an NSAID (usually aspirin or ibuprofen) regularly for 5 years or more had a 40% lower risk of breast cancer than those who did not report such use, Dr. Randall E. Harris and his colleagues at the Ohio State University Comprehensive Cancer Center have found.

COLUMBUS, Ohio--Women who said they used an NSAID (usually aspirinor ibuprofen) regularly for 5 years or more had a 40% lower riskof breast cancer than those who did not report such use, Dr. RandallE. Harris and his colleagues at the Ohio State University ComprehensiveCancer Center have found.

This case-control study involved 303 breast cancer patients diagnosedat the University's Arthur G. James Cancer Hospital and 906 controls(women who underwent screening mam-mography and had no detectablebreast disease). Risk factor data were collected by personal interviewsat the time of diagnosis or screening.

Significantly more women in the control group (27%) reported regularNSAID use than did the breast cancer patients (19%). Calculationof odds ratios showed a reduction in risk of 36% for those whotook NSAIDs three or more times a week for 6 months or more, anda reduction of 40% among those who used NSAIDs seven times a weekfor 5 years or more.

These results, published in Oncology Reports (2:591-592, 1995),are supported by an earlier study by Dr. Harris' team that matched744 newly diagnosed breast cancer patients with 767 controls drawnfrom hospital patients with medical conditions unrelated to breastcancer.

That study found a 37% reduction in breast cancer risk among womenwho reported using NSAIDs at least three times a week for at least5 years (Prev Med 24:119-120, 1995).

Related Videos
Pegulicianine-guided breast cancer surgery may allow practices to de-escalate subsequent radiotherapy, says Barbara Smith, MD, PhD.
Barbara Smith, MD, PhD, spoke about the potential use of pegulicianine-guided breast cancer surgery based on reports from the phase 3 INSITE trial.
Carey Anders, MD, an expert on breast cancer
Carey Anders, MD, an expert on breast cancer
Carey Anders, MD, an expert on breast cancer
Carey K. Anders, MD, an expert on breast cancer
A panel of 4 experts on breast cancer seated at a long table
A panel of 4 experts on breast cancer seated at a long table